ÂÜÀòÂÒÂ×

His leadership, strategic vision, extensive academic and industrial background, technical experience, scientific knowledge and regulatory expertise, along with his innovative and problem-solving skills, are invaluable company assets. Spiro is the inventor and author of more than 130 international and domestic patents and patent-publications, and 200 scientific papers, books, and other publications and presentations in the fields of pharmaceutics, pharmaceutical technology, pharmacokinetics and analytical chemistry. He is the company’s chief formulator leading its Unique Product Selection process and closely advising and supervising its formulation scientists. Spiro is also the inventor of several newly developed proprietary drug delivery systems currently used by the company that are either patented or actually remaining trade secrets by design. On May 14, 2019, Dr. Spireas received an honorary Doctor of Science (D.Sc.) degree from Long Island University, Brooklyn, New York. Dr. Spireas also holds a Ph.D. degree in Pharmaceutics and an M.S. degree in Industrial Pharmacy, both from St. John's University, Jamaica, New York, and a B.S. degree in Pharmacy from the Hellenic National University, Athens, Greece. Prior to forming Sigmapharm Laboratories, Spiro served as the Vice President of Research and Development for URL Pharma, Inc. (formerly URL/Mutual), Philadelphia, PA, where he developed various unique generic products including Felodipine extended release (ER) tablets, which remained for more than four years the only marketed generic equivalent to Astra-Zeneca's Plendil® ER tablets. Prior to joining the industry, Dr. Spireas served as a Professor of Pharmacy at the Arnold & Marie Schwartz College of Pharmacy of Long Island University, Brooklyn, New York, where he received his tenure as an Associate Professor, taught several graduate and undergraduate courses, consulted for the pharmaceutical and nutritional industries and conducted extensive research producing more than 20 Ph.D. and M.S. thesis dissertations.